UCB CELLTECH

ACTIVE

216 Bath Road, Slough, United Kingdomwww.ucb.com/worldwide/ukSubsidiary11–50 employeesEstablished: 1925-01-01

Part of ucb pharma sa (belgium)

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1925

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

62.5%

Phase 2

37.5%

Trial Status Distribution

Completed

75.0%

Terminated

25.0%

Clinical Trials

Trials sponsored by this organization (8)

A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy Subjects

Phase 1

Completed

interventional

Mar 201612 participants

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Phase 2

Terminated

interventional

Oct 201527 participants

Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis

Phase 2

Completed

interventional

Apr 2015159 participants

Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

Phase 1

Completed

interventional

Aug 201460 participants

A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers

Phase 1

Completed

interventional

Jul 201441 participants

Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis

Phase 1

Completed

interventional

May 201453 participants

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Phase 1

Completed

interventional

Nov 201239 participants

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents

Phase 2

Terminated

interventional

Apr 200999 participants

Approvals

No approval data available

News

No news articles found

Back to Organizations